A trial of a vaccine called DCVax-L for glioblastoma multiforme

Coronavirus and cancer

We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.

Read our information about coronavirus and cancer

Coronavirus and cancer

We know it’s a worrying time for people with cancer, we have information to help. If you have symptoms of cancer contact your doctor.

Read our information about coronavirus and cancer

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Brain (and spinal cord) tumours

Status:

Closed

Phase:

Phase 3

This is a trial looking at personalised vaccines to treat a type of brain tumour called glioblastoma multiforme.

If you have a glioblastoma multiforme (GBM), your treatment may include surgery, radiotherapy and chemotherapy. In this trial, doctors want to see if adding a vaccine called DCVax-L helps.

To make DCVax-L, researchers use some of your own white blood cells to make what are called dendritic cells. They mix the dendritic cells with proteins taken from your brain tumour to make a dendritic cell vaccine Open a glossary item. It can help your immune system to recognise and kill cancer cells.

The aim of the trial is to see if DCVax-L helps people with glioblastoma multiforme.

Who can enter

You may be able to enter this trial if

  • You have recently been diagnosed with a type of brain tumour called a glioblastoma multiforme and are having surgery to remove it at a hospital participating in the trial, followed by radiotherapy and the chemotherapy drug temozolomide
  • There is enough material from your tumour and enough white blood cells to make the vaccines
  • You have satisfactory blood test results
  • You are able to care for yourself, even if you can’t carry out all your normal activities or do active work (Karnofsky performance status of at least 70)
  • You are at least 18, but no more than 70 years of age

It may only be possible to confirm the type of brain tumour you have when you have surgery. The researchers will look at a sample removed during the operation to check that your tumour is a glioblastoma multiforme.

You cannot enter this trial (or may not be able to continue at some point) if you

  • Have a tumour that has grown into both sides of your brain or has  spread elsewhere
  • Are still taking steroids unless it is a low dose – the trial team can advise you about this
  • Have implants containing chemotherapy (Gliadel wafers) put in when you have surgery
  • Have ever had any other type of chemotherapy
  • Have had another type of cancer unless it was a very early stage or was successfully treated at least 5 years ago – you may be able to take part if you’ve had a low grade glioma in the past as long as you didn’t have chemotherapy - the trial team can advise you about this
  • Have an autoimmune disease Open a glossary item or other problems with your immune system
  • Have had an organ transplant
  • Take any other medication that has an anti cancer effect or can affect your immune system
  • Are known to have HIV, hepatitis B, hepatitis C or viruses called HTLV-1 or HTLV-2
  • Have an infection that needs treating (if you’ve been taking antibiotics, you must have finished them at least a week before having the first injection of the trial treatment)
  • Have inherited genetic changes that put you at a high risk of getting cancer
  • Have certain heart problems or any other serious medical condition – the trial team can advise you about this
  • Are allergic to anything used in the vaccines
  • Are pregnant or breastfeeding

Trial design

This phase 3 trial will recruit about 300 people.

The trial team will talk to you about joining the trial before you have surgery. This is because they need your permission to get samples of your tumour that they would be able to use to make the vaccine.

Agreeing to this doesn’t mean that you will definitely be able to take part in the trial. Whether or not you can take part depends on the results of MRI scans after surgery and radiotherapy, whether the researchers are able to get enough material from your tumour to make the vaccine, and other factors.

If it turns out that you can’t take part in the trial, the sample of your brain tumour will be used for research, unless you tell the trial team that you want it to be destroyed instead.

If it looks as though you can take part in the trial, the next step is for the researchers to get some of your white blood cells to make the vaccine. The way they do this is described in the hospital visits section below.

You then have radiotherapy and chemotherapy. After finishing radiotherapy, you have another MRI scan to check that your tumour hasn’t started growing again. You can only take part in this trial if your doctors are sure that your tumour hasn’t started to grow again.

Sometimes, it isn’t possible to tell from the results of a scan whether or not a tumour has started growing again. It may look as though there is growth, but it could be swelling (inflammation) or scarring after surgery. If the doctors are unsure what the results are showing, you have another MRI scan 2 months later. If this shows there is no growth, you may then be able to take part in the trial.

The trial is randomised. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.  And neither of you will know which group you are in. This is called a double blind trial.

For every 3 people who take part, 2 have DCVax-L injections and 1 has a dummy injection (placebo Open a glossary item).

DCVax-L for glioblastoma multiforme trial diagram

You have the vaccine (or dummy) injections under the skin on your upper arm. You have them 3 times in the first month, 4 more times over the next year and then every 6 months until the end of treatment. You have 2 separate injections each time.

If scans show that your tumour starts to grow again during treatment, you can start having DCVax-L injections regardless of the group you are in. This is called a ‘crossover option’.  You may have already been having the vaccine, or you may have been having the dummy drug – neither you nor your doctor will know. If you go into the crossover option, you still won’t know which treatment you’d been having up until then. But you will definitely be having the vaccine from then on.

Your doctor will tell you if your tumour has started to grow again and then it is your choice whether you want to definitely start having the vaccine or not.

If you do, you start the treatment from the beginning, so you have the vaccine 3 times in the next month, 4 more times over the next year and then every 6 months. You may have other treatment as well if your doctor thinks it is right for you.

Hospital visits

After having surgery to remove your brain tumour, you see the trial team and have some more tests. The tests include

  • Physical examination
  • Blood tests
  • Urine tests
  • MRI scan

If results of these tests show that you can take part in the trial, the researchers need to collect some of your white blood cells to prepare the dendritic cells.

To collect the blood cells, they put a small tube into a vein in each of your arms. One tube removes blood and passes it into a machine that removes the white blood cells. You then have the rest of your blood back through the tube in your other arm. This is called leukapheresis. It takes about 4 hours.

If the researchers don’t get enough cells to make the vaccine, you may have leukapheresis again.

You have another MRI scan after finishing radiotherapy to check that you can have the trial treatment. If you can, you have the vaccine (or dummy injections) up to 10 times over about 2½ years. You will be at the hospital for 2 to 3 hours each time.

During treatment, you see the trial team and have blood tests and an MRI scan every 2 months.

After you finish treatment, the trial team will continue to check your medical notes and will contact you regularly to see how you are.

Side effects

As this is a new treatment, there may be side effects we don’t know about yet. In earlier trials of DCVax-L injections, the side effects have included

  • A reaction at the injection site such as redness, warmth and swelling, itching, or pain
  • High temperature (fever)
  • Tiredness (fatigue)
  • Headache
  • Muscle or joint pain

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Keyoumars Ashkan

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Northwest Biotherapeutics

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

8494

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Rhys was only four years old when he was diagnosed with a brain tumour

A picture of Rhys

"He went through six operations and was placed on a clinical trial so he could try new treatments.”

Last reviewed:

Rate this page:

Currently rated: 4.1 out of 5 based on 14 votes
Thank you!
We've recently made some changes to the site, tell us what you think